Glaukos

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Glaukos reports robust Q4 earnings, sets ambitious growth plans for 2023

Glaukos delivered strong financial performance in Q4 2022 and outlined ambitious plans for 2023, focusing on innovation and market expansion. Despite staffing challenges and operating expense growth, the company remains optimistic about its growth prospects. Opportunities in advancing key products and addressing market dynamics position Glaukos for continued success.

Glaukos reports strong Q1 earnings, eyes international market opportunities

Glaukos delivered robust financial results in Q1 2023, showcasing growth in key franchises and advancing its pipeline. The company faces challenges in operational efficiency and market expansion but holds opportunities in international markets and innovative product offerings. Overall, Glaukos remains well-positioned for future growth and success.

Glaukos reports record Q2 sales, eyes international growth opportunities

Glaukos delivered strong Q2 results, with a focus on strategic investments for iDose launch and maintaining growth momentum. Challenges include reimbursement changes and healthcare trend normalization. Opportunities lie in international expansion and new product launches.

Glaukos reports robust Q3 sales, eyes early glaucoma intervention

Glaukos shows strong performance with sales growth and strategic developments.
Facing challenges in market share and FDA concerns but seizing growth opportunities.
Confidence in ongoing projects and commitment to advancing glaucoma therapies.
Strategic focus on innovation and market expansion in the glaucoma sector.

Glaukos achieves record sales, focuses on innovation and market growth

Glaukos delivered strong financial performance, with a focus on innovation and market leadership in the ophthalmic space.
The company's strategic strengths lie in its product portfolio, market access initiatives, and commitment to driving change in the standard of care.
Challenges include managing physician time allocation, balancing growth strategies, and ensuring successful product launches.
Opportunities for Glaukos include increased adoption of innovative products, pipeline advancements, and continued investment in driving future growth.

Glaukos reports record sales and raises guidance for 2024

Glaukos is on track for strong financial performance with record sales and increased guidance. The company faces challenges with iDose adoption and reimbursement timelines but sees opportunities for growth in various product lines.

Glaukos reports record Q2 sales, raises guidance amid innovation focus

Glaukos delivered strong financial performance in Q2 2024, with record net sales and raised full year guidance, driven by robust sales across key franchises.
The company's focus on innovation, balance sheet strengthening, and market expansion positions it well for future growth and competitive advantage.
While facing regulatory and operational challenges, Glaukos has opportunities to capitalize on market trends, product adoption, and international expansion.
Navigating these challenges and leveraging opportunities will be crucial for Glaukos to sustain growth momentum and enhance shareholder value.

Glaukos reports record Q3 sales, eyes growth through product launches

Glaukos delivered strong financial performance in Q3 2024, with record net sales and raised full year guidance. The company's focus on product innovation, market expansion, and reimbursement strategies positions it well for future growth. While challenges in financial restructuring and market access exist, opportunities in product launches and international expansion offer promising prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that U.S. Phase 3 pivotal trial results for its next-generation corneal cross-linking iLink™ therapy for the treatment of keratoconus, known as Epi-on, met the study's primary efficacy endpoint, demonstrating a statistically significant improvement in

Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2020 financial results after the market close on Thursday, February 25, 2021. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February

Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2020. Preliminary and unaudited total net sales for the fourth quarter of 2020 are expected to be approximately $73 million, consisting of approximately $58 mi

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite™ Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal intraocular pressure (IOP) in patients with open-angle glaucom

U.S. IDE Trial Results for Glaukos' iStent infinite™ Show Substantial Reduction in IOP

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 24-month interim analysis of the ongoing 36-month Phase 2b clinical trial conducted under a U.S. Investigat

Glaukos' iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST. A live and archived webcast for this event will be available in the Investors section of t

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Glaukos (GKOS) Up 24.3% Since Last Earnings Report: Can It Continue?

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3

Glaukos Corporation (GKOS) CEO Tom Burns on Q3 2020 Results - Earnings Call Transcript

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2020. Key highlights include: Net sales of $64.8 million in Q3 2020, compared to $58.5 million in Q3 2019. Glaucoma net sales of $51.9 million and Corneal Health net sales of $12.9 million in

Glaukos Corporation Announces Third Quarter 2020 Financial Results

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Glaukos (GKOS) Q3 Earnings Expected to Decline

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2020 financial results after the market close on Thursday, November 5, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on November 5, 2020. A link

Glaukos Corporation to Release Third Quarter 2020 Financial Results after Market Close on November 5

San Diego, California--(Newsfile Corp. - September 29, 2020) -  The Shareholders Foundation, Inc. announces that a lawsuit was filed for investors who formerly held Avedro, Inc. (AVDR) shares.Investors, who held shares of Avedro, Inc. (Nasdaq: AVDR) and received Glaukos Corporation (NYSE: GKOS) shares as a result of the takeover, might have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.On August 7, 2019, Avedro, Inc's Board of...

NOTICE For Investors In NYSE: GKOS Shareholder Notice: Update in Lawsuit for Investors who held Avedro, Inc. (AVDR) shares announced by Shareholders Foundation

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow LLP, a leading investor rights law firm, announces it is investigating potential securities claims on behalf of former shareholders of Avedro Inc. (NASDAQ: AVDR) concerning allegations that Glaukos Corp.

INVESTIGATION ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of the Merger of Avedro, Inc. and Glaukos Corporation and Strongly Encourages Investors to Contact the Firm

Glaukos (GKOS) Down 1.6% Since Last Earnings Report: Can It Rebound?

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference on Thursday, September 10, 2020 at 11:00 a.m.

Glaukos Announces Participation in September Investor Conferences

Glaukos Is Still A Good Long-Term Value Despite A Tough 2020

SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Glaukos Corporation (NYSE: GKOS) ("Glaukos" or the "Company") for violations of federal securities laws.

Glaukos /Avedro (GKOS) Alert: Investigation into the Glaukos Acquisition of Avedro; Avedro Investors Receiving Glaukos Shares Encouraged to Contact Johnson Fistel

Glaukos' (GKOS) second-quarter results reflect fall in revenues partially mitigated by contribution from Avedro buyout.

Glaukos (GKOS) Loses 17.1% Despite Q2 Earnings & Revenues Beat

Glaukos Corporation (GKOS) Tom Burns on Q2 2020 Results - Earnings Call Transcript

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2020.

Glaukos Corporation Announces Second Quarter 2020 Financial Results

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2020 financial results after the market close on Thursday, August 6, 2020.

Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6

Investor confidence is high on Glaukos (GKOS) stock, thanks to solid prospects.

News for Glaukos Stock (GKOS)